Selected abstracts Pathogen Inactivation

16.30 – 16.45 COMPARING CLINICAL USE, EFFECTIVENESS, AND RISKS ACROSS TRANSITION FROM FRESH FROZEN PLASMA TO SOLVENT/DETERGENT PLASMA IN THE NETHERLANDS – N. Saadah, Netherlands

16.45 – 17.00 COMBINING UVC-PATHOGEN INACTIVATION AND COLD-STORAGE: A NOVEL APPROACH TO IMPROVE PLATELET SAFETY AND EXTEND THE SHELF-LIFE – D. Marks, Australia

17.00 – 17.15 THREE YEARS ROUTINE EXPERIENCE OF MANUAL PRODUCTION OF DOUBLE-DOSE BUFFY COAT PLATELETS AND PATHOGEN INACTIVATION SYSTEM INTERCEPT: IMPACT ON ECONOMY, BLOOD SAFETY AND BLOOD COMPONENT QUALITY – H.S. Ahlzén, Sweden

17.15 – 17.30 NO INTERCEPT (S-303/GLUTATHIONE)-SPECIFIC ANTIBODIES DETECTED IN A PHASE III, RANDOMIZED, CONTROLLED STUDY TO EVALUATE PATHOGEN-INACTIVATED RED BLOOD CELLS IN THALASSEMIA MAJOR PATIENTS (SPARC) – L. Annandale, United States